3SBio Inc. (HKG:1530)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 39.79B |
| Revenue (ttm) | 19.69B |
| Net Income (ttm) | 9.44B |
| Shares Out | 2.50B |
| EPS (ttm) | 3.82 |
| PE Ratio | 4.17 |
| Forward PE | 12.60 |
| Dividend | 0.25 (1.57%) |
| Ex-Dividend Date | Jul 21, 2026 |
| Volume | 25,428,452 |
| Average Volume | 36,433,408 |
| Open | 16.28 |
| Previous Close | 16.06 |
| Day's Range | 15.80 - 16.74 |
| 52-Week Range | 14.81 - 36.80 |
| Beta | 0.47 |
| RSI | 37.30 |
| Earnings Date | Aug 21, 2026 |
About 3SBio
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, ... [Read more]
Financial Performance
In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.
Financial numbers in CNY Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for 1530 stock is "Strong Buy." The 12-month stock price target is $36.35, which is an increase of 128.47% from the latest price.
News
3SBio Earnings release: H2 2025
3SBio released its H2 2025 earnings on March 30, 2026, summarizing the period's financial results.
3SBio Annual report: H2 2025
3SBio has published its H2 2025 annual report on March 30, 2026.
3SBio Quarterly report: H1 2025
3SBio has published its H1 2025 quarterly earnings report on August 29, 2025.
3SBio Earnings release: H1 2025
3SBio released its H1 2025 earnings on August 29, 2025, summarizing the period's financial results.
Pfizer Signs $6B Deal with 3SBio for China-Based Cancer Drug
American drug giant Pfizer ($PFE) has entered into a $6 billion exclusive licensing deal with China’s 3SBio Inc. ($HK:1530) for its experimental cancer drug, SSGJ-707. According to the terms of…